Shots:
- Junshi Biosciences has reported the final analysis from the P-III (NEOTORCH) trial assessing toripalimab + Pt-containing doublet CT vs PBO + CT as perioperative treatment in 501 pts with resectable stage II-III NSCLC pts
- Trial improved EFS, with mEFS not reached vs 15.1mos. for CT alone, reducing risk of recurrence, progression, or death by 60%, while increasing pCR rates ~25-fold (24.8% vs 1%) & MPR rates ~6-fold (48.5% vs 8.4%); a favorable OS trend was also observed
- Additionally, Junshi Biosciences plans to submit an sNDA for Toripalimab to regulatory authorities in the near future
Ref: Globenewswire | Image: Junshi Biosciences | Press Release
Related News: Junshi Biosciences Reports NMPA Acceptance of the NDA for Roconkibart (IL-17A) to Treat Moderate to Severe Plaque Psoriasis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
